Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 201

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Expression of PD-L1 and prognosis in breast cancer: a meta-analysis

Open access
Zhang, Minghui, Sun, Houbin, Zhao, Shu, Wang, Yan, Pu, Haihong, Wang, Yan, Zhang, Qingyuan·2017·Oncotarget

Abstract

// Minghui Zhang 1, * , Houbin Sun 2, * , Shu Zhao 1, * , Yan Wang 3 , Haihong Pu 1 , Yan Wang 1 and Qingyuan Zhang 1 1 Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150081, China 2 Department of Intervention, Harbin Medical University Cancer Hospital, Harbin, 150081, China 3 Department of Medical Oncology, Heilongjiang Provincial Hospital, Harbin, 150000, China * These authors have contributed equally to this work Correspondence to: Qingyuan Zhang, email: zhma1965210@163.com Keywords: meta-analysis, prognosis, programed death-ligand 1, breast cancer Received: July 04, 2016 Accepted: January 31, 2017 Published: February 20, 2017 ABSTRACT The associations between programmed cell death ligand 1 (PD-L1) and the prognosis of various cancers have always been a research topic of considerable interest. However, the prognostic value of PD-L1 in breast cancer patients remains a controversial subject. We aimed to assess the association between PD-L1 protein expression and clinicopathological features and the impact of this relationship on breast cancer survival. We performed a systematic search of the PubMed, EMBASE, and Cochrane Library databases to determine the correlations among PD-L1 expression, clinicopathological features and overall survival (OS). A total of 5 studies containing 2,546 cases were included in the analysis. The combined hazard ratio (HR) and its 95% confidence interval (CI) for OS were 1.76 (95% CI 1.09–2.82; P =0.02) for patients with tumors exhibiting PD-L1 overexpression. The pooled odds ratios (ORs) indicated that PD-L1 expression was associated with positive lymph node metastasis, higher histological grades, estrogen receptor (ER)-negativity, and triple-negative breast cancer (TNBC). Our findings indicate that PD-L1 expression is a promising biomarker for the prognosis of breast cancer, and may be helpful to clinicians aiming to select the appropriate immunotherapy for breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.15532

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 201

Metadata

Authors
Zhang, M., Sun, H., Zhao, S., Wang, Y., Pu, H., Wang, Y., & Zhang, Q.
Venue
Oncotarget
Published
2017-02-20
Volume
8
Issue
19
Pages
31347-31354
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2589193607
Cited by
201
References
4
FWCI
2.86
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. https://app.cochat.ai/papers/10.18632/oncotarget.15532
The paper
Zhang, M., Sun, H., Zhao, S., Wang, Y., Pu, H., Wang, Y., & Zhang, Q. (2017). Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. Oncotarget. https://doi.org/10.18632/oncotarget.15532

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.